Asset Details
Do you wish to reserve the book?
Impact of Visceral and Hepatic Fat on Cardiometabolic Health
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of Visceral and Hepatic Fat on Cardiometabolic Health
Do you wish to request the book?
Impact of Visceral and Hepatic Fat on Cardiometabolic Health
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of Visceral and Hepatic Fat on Cardiometabolic Health
2024
Overview
Purpose of Review
Body fat distribution plays a significant role in the cardiometabolic consequences of obesity. We review the impact of visceral and hepatic fat and highlight important interventions.
Recent Findings
Several epidemiologic studies have established a clear association between visceral fat and cardiovascular disease. The association between hepatic fat and cardiovascular disease is less clear with discordant results. Novel evidence demonstrates sodium glucose co-transporter-2 (SGLT2) inhibitors facilitate modest weight loss and reductions in ectopic fat depots in patient with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have been associated with decreased visceral/hepatic fat and reductions in MACE in populations with type 2 diabetes and with overweight/obesity.
Summary
Clear associations between visceral fat and cardiometabolic outcomes have been established, whereas the impact of hepatic fat remains less clear. Lifestyle modification and pharmacologic interventions remain the initial therapies, while surgical intervention is associated with improved long-term outcomes. Emerging therapies have demonstrated a profound impact on body fat distribution and cardiometabolic risk.
Publisher
Springer US,Springer Nature B.V
Subject
/ Cardiometabolic Disease (DM and CV) (CJ Lavie
/ Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)
/ Cardiometabolic Risk Factors
/ Cardiovascular Diseases - prevention & control
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - physiopathology
/ Glucagon-Like Peptide-1 Receptor Agonists
/ Humans
/ Medicine
/ Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
